Table 1. Characteristics of studies included in the meta-analysis.
| Study | lncRNAs | Country | Follow-up | Cut-off | Method | Sample | Outcome | HR(95% CI) | HR | NOS |
|---|---|---|---|---|---|---|---|---|---|---|
| (month) | size | High/Low | estimate | score | ||||||
| Droop 2017[22] | UCA1 | Germany | 22.7(0.2–198) | Median | qRT-PCR | 106 | OS | 0.576(0.367–0.876) | Reported | 6 |
| Droop 2017[22] | Linc-UBC1 | Germany | 22.7(0.2–198) | Median | qRT-PCR | 106 | OS | 0.953(0.619–1.468) | Reported | 6 |
| Droop 2017[22] | TUG1 | Germany | 22.7(0.2–198) | Median | qRT-PCR | 106 | OS | 0.579(0.375–0.895) | Reported | 6 |
| Droop 2017[22] | ncRAN | Germany | 22.7(0.2–198) | Median | qRT-PCR | 106 | OS | 0.416(0.543–1.287) | Reported | 6 |
| Droop 2017[22] | MALAT1 | Germany | 22.7(0.2–198) | Median | qRT-PCR | 106 | OS | 0.547(0.353–0.848) | Reported | 6 |
| Droop 2017[22] | H19 | Germany | 22.7(0.2–198) | Median | qRT-PCR | 106 | OS | 0.904(0.587–1.390) | Reported | 6 |
| Droop 2017[22] | GAS5 | Germany | 22.7(0.2–198) | Median | qRT-PCR | 106 | OS | 0.707(0.459–1.091) | Reported | 6 |
| Zhang 2016[23] | UNMIBC | China | 36(10–69) | FC>1.5 | qRT-PCR | 75 | RFS | 2.362(1.504–4.837) | Reported | 7 |
| Duan 2016[24] | MEG3 | China | 57(4–76) | Median | qRT-PCR | 59 | RFS | 2.222(1.013–4.878) | Reported | 6 |
| Duan 2016[24] | SNHG16 | China | 57(4–76) | Median | qRT-PCR | 59 | RFS | 0.613(0.286–1.312) | Reported | 6 |
| Duan 2016[24] | MALAT1 | China | 57(4–76) | Median | qRT-PCR | 59 | RFS | 1.631(0.756–3.521) | Reported | 6 |
| Iliev 2016[25] | TUG1 | Czech Republic | 30(12–104) | ROC | qRT-PCR | 47 | OS | 2.54 (1.13–5.74) | Reported | 8 |
| Zhao 2015[26] | SPRY4-IT1 | China | 60(Total) | Median | qRT-PCR | 68 | OS | 3.716(2.084–6.719) | Reported | 7 |
| Martínez-Fernández 2015[27] | HOTAIR | Spain | 28(1–36) | Median | qRT-PCR | 64 | OS | 2.21(1.02–4.81) | Survival curve | 6 |
| Chen 2015[28] | n336928 | China | 60(Total) | Median | qRT-PCR | 98 | OS | 2.377(1.007–5.610) | Reported | 8 |
| Tan 2015[29] | TUG1 | China | 60(Total) | NA | qRT-PCR | 54 | OS | 2.84(1.21–7.20) | Survival curve | 6 |
| Fan 2014[30] | MALAT1 | China | 30(Total) | Median | qRT-PCR | 95 | OS | 1.26(0.68–2.13) | Reported | 8 |
FC = fold change; ROC = receiver operating characteristic; OS = overall survival; RFS = recurrence-free survival; HR: hazard ratio; 95% CI: confidence intervals; UCA1 = urothelial carcinoma associated 1 RNA = ; Linc-UBC1 = Up-regulated in bladder cancer 1; H19 = long noncoding RNA 19; GAS5 = growth arrest-specific 5; UNMIBC = Up-regulated in MIBC; TUG1 = taurine upregulated gene 1; MEG3 = maternally expressed gene 3; SNHG16 = small nucleolar RNA host gene 16; Malat1 = metastasis associated lung adenocarcinoma transcript 1; SPRY4-IT1 = SPRY4 intronic transcript 1; HOTAIR = HOX antisense intergenic RNA.